First reimbursement of Yuhan Pregabalin 75mg CR

Used in the initial dose of patients with moderate renal impairment

Competing with Lyrica CR extended-release tablet 82.5mg

Yuhan Pregabalin SR 300mg

Yuhan Corporation became the first company in Korea to list Pregabalin 75mg SR tablets for benefit.

 

This drug is used as an initial dose for patients with moderate renal impairment.

 

According to the industry on the 6th, Yuhan Pregabalin SR 75mg has been listed at 513 won per tab since May.

 

Various doses of Pregabalin, such as 25 mg, 50 mg, 150 mg, and 300 mg, as well as 75 mg for neuropathic pain, were registered for reimbursement.

 

Pregabalin is usually administered at a starting dose of 150 mg per day for neuropathic pain.

 

However, in patients with renal impairment, lower doses are used first.

 

Pregabalin 75 mg is used as a starting dose for patients with moderate renal impairment.

 

In the meantime, only 150mg and 300mg, which are the main doses, have been developed for SR.

 

Pregabalin 75mg extended-release tablet is the first time for Yuhan.

 

This drug is intended for use in low doses in patients with moderate renal impairment.

 

As it is SR, it is taken once a day.

 

Considering that the existing 75mg fast-acting tablet was taken 2-3 times a day, it is expected that the convenience of taking it will increase for patients.

 

Although there is no 75mg sustained-release tablet, Original Viatris is offering Lyrica CR extended-release 82.5mg for patients with moderate renal dysfunction.

 

It is analyzed that Pregabalin 75mg was developed targeting Lyrica CR 82.5mg.

 

In terms of price, Pregabalin 75mg is cheaper than Lyrica CR 82.5mg.

 

Yuhan products are priced at 513 won, while Viatris products are priced at 732 won, which is more than 200 won higher.

 

Lyrica is a blockbuster product that recorded 69 billion won in outpatient prescriptions (UBIST) last year.

 

However, the SR market is small.

 

Lyrica CR's outpatient prescriptions last year were only 900 million won.

 

As such, the extended-release tablet market, which is highly convenient to take, has great potential for growth, and generics are also launching products one after another targeting this.

 

Yuhan was the first to receive approval and is evaluated as having established an unrivaled area in the domestic Pregabalin 75mg market.

 

Yuhan is already rolling out Pregabalin 50mg and 300mg SR through reimbursement.

 

In the pregabalin market, in the Pregabalin market, attention is focused on whether Yuhan's efforts to develop SR will bear fruit.